deltatrials
Active Not Recruiting PHASE1/PHASE2 NCT04863885

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial Carcinoma

Sponsor: Bristol-Myers Squibb

Conditions Metastatic Urothelial Carcinoma
Interventions Ipilimumab Nivolumab Sacituzumab govitecan
Updated 20 times since 2021 Last updated: Dec 11, 2025 Started: Apr 30, 2021 Primary completion: Sep 12, 2025 Completion: Oct 31, 2027

This PHASE1/PHASE2 trial investigates Metastatic Urothelial Carcinoma and is currently ongoing. Bristol-Myers Squibb leads this study, which shows 20 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

20 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Nov 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Jun 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Mar 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  5. Dec 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

▶ Show 15 earlier versions

  1. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Feb 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jan 2024 — Feb 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Dec 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Aug 2023 — Dec 2023 [monthly]

    Recruiting PHASE1_PHASE2

  9. Feb 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  10. Nov 2022 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

  11. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

  12. Mar 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  13. Oct 2021 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jun 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  15. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Gilead Sciences
  • H. Lee Moffitt Cancer Center and Research Institute
Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Tampa, United States